Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 5/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.59 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.58 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | GSK3A | P49840 | 2/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24299397 | 1.00 | HINT1 (0.62) | HINT1ADORA3NT5ESTING1PDE3B | |
| SCHEMBL16114092 | 1.00 | HINT1 (0.62) | HINT1ADORA3NT5ESTING1PDE3B | |
| SCHEMBL19938159 | 1.00 | HINT1 (0.62) | HINT1ADORA3NT5ESTING1PDE3B | |
| SCHEMBL13833323 | 1.00 | HINT1 (0.62) | HINT1ADORA3NT5ESTING1PDE3B | |
| SCHEMBL2510562 | 1.00 | HINT1 (0.62) | HINT1ADORA3NT5ESTING1PDE3B | |
| SCHEMBL27221934 | 0.99 | HINT1 (0.61) | HINT1ADORA3NT5ESTING1PDE3B | |
| Phosphoric Acid SCHEMBL1299515 | 0.96 | NT5E (0.63) | HINT1ADORA3NT5ESTING1PDE3B | |
| Phosphoric Acid SCHEMBL25402859 | 0.96 | NT5E (0.63) | HINT1ADORA3NT5ESTING1PDE3B | |
| SCHEMBL21232923 | 0.92 | HINT1 (0.56) | HINT1ADORA3NT5ESTING1PDE3B | |
| Phosphoric Acid SCHEMBL17505120 | 0.92 | NT5E (0.61) | HINT1ADORA3NT5ESTING1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0787138-B1 | RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY | IMMUNOMEDICS INC (US) | 2006-06-28 | — | — | EP | claimed |
| EP-0787138-A4 | RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY | IMMUNOMEDICS INC (US) | 2000-03-08 | — | — | EP | claimed |
| US-5976492-A | Radioactive phosphorus labeled proteins for targeted radiotherapy | IMMUNOMEDICS, INC. (US) | 1999-11-02 | — | — | US | claimed |
| US-5728369-A | Radioactive phosphorus labeling of proteins for targeted radiotherapy | IMMUNOMEDICS, INC. (US) | 1998-03-17 | — | — | US | claimed |
| EP-0787138-A1 | RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY | Immunomedics, Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| WO-1996011208-A1 | RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY | IMMUNOMEDICS, INC. (US) | 1996-04-18 | — | — | WO | claimed |
| WO-2024119117-A1 | MODIFIED 5' CAP FOR MRNA AND METHODS OF USE THEREOF | PRIME MEDICINE, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240166675-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2024-05-23 | — | — | US | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210230638-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-10513520-B2 | Sulfamide and sulfamate inhibitors of hHint1 | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2019-12-24 | — | — | US | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| WO-2008112980-A2 | METHOD AND SYSTEM FOR ASSEMBLY OF MACROMOLECULES AND NANOSTRUCTURES | INCITOR, LLC (US) | 2008-09-18 | — | — | WO | disclosed |
| EP-0787138-B1 | RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY | IMMUNOMEDICS INC (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-0787138-A4 | RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY | IMMUNOMEDICS INC (US) | 2000-03-08 | — | — | EP | disclosed |
| US-5976492-A | Radioactive phosphorus labeled proteins for targeted radiotherapy | IMMUNOMEDICS, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5728369-A | Radioactive phosphorus labeling of proteins for targeted radiotherapy | IMMUNOMEDICS, INC. (US) | 1998-03-17 | — | — | US | disclosed |
| EP-0787138-A1 | RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY | Immunomedics, Inc. (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996011208-A1 | RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY | IMMUNOMEDICS, INC. (US) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10513520-B2 | Sulfamide and sulfamate inhibitors of hHint1 | GRIN1, OPRL1, GRIN3A | HINT1 131/4885ADORA3 450/4885NT5E 2442/4885 |
| US-20240166675-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, NUDT1, NT5C3B | HINT1 220/4885ADORA3 652/4885NT5E 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.